A solution to advanced and recurrent cases of endometriosis : FDA approves Immunotherapy for endometrial cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
The FDA is granted accelerated approval to Jemperli (dostarlimab)) for treatment of patients with recurrent and advanced endometrial cancer that has progressed with the prior treatment with the chemotherapy.

Uterine or endometrial cancer originates in the layers of cells in the uterus lining called the endometrium and involves uncontrolled or unregulated growth of cells to form cancerous tumours. Uterine cancer develops in the layers of cells that line the uterus. The lining of the uterus is called the endometrium which is why this condition is also known as endometrial cancer. Uterine cancer is the most common genital cancer and fourth most common cause of cancer. Upto 3 million people are diagnosed with uterine or endometrial cancer every year.

Types of endometrial cancer 

There are two main types of cancer that form in the endometrium which are as follows:

Endometrial adenocarcinomas: This cancer originates in the secreting tissue and one of the most common types of cancer 

Uterine sarcomas: This is the less common form of carcinoma of the uterus and originates in the connective tissue or the muscles of the uterus. 

Endometrial cancer is often detected at an early stage and has a high cure and success rate. Good chances of improvement are seen if Endometrial cancer is detected before it spreads to the entire uterus. 

Causes of endormetrial cancer 

All cancers develop when an uncontrolled group of cells divide abnormally and multiplies in the body at a faster rate forming a tumour. As most of the cancer, doctors and researchers are unable to determine the main cause of endometrial cancer. There is some problem associated with the immune system where it is weakened thus affecting the body overall health causing weight loss and fever. There are some risk factors which are very important and likely contribute to endometrial cancer. They include: 

Obesity:Excess body fat spikes estrogen levels in women and correlates to high cancer risk. 

Never been pregnant: Women who have never given birth to any child for unexplained reasons are also likely and have higher risk of developing endometrial cancer.

Late menopause : Women who begin menopause after 55 years of age are at higher risk of endometrial cancer. This could be due to fluctuating levels of estrogens in women making them more prone to endometrial cancer.

Early puberty : Women who develop early menarche are at higher risk of having endometrial cancer and should take necessary precautions of fluctuating hormonal level. 

Hereditary :Women with genetics of endometrial cancer have increased chances of contracting endometrial cancer 

 Symptoms of endometrial cancer 

Heavy abnormal bleeding  Pain in the abdomen Postmenoupasudal bleeding  Abnormal and irregular periods Prolonger bleeding  Unexpected weight loss  Pelvic pain  Painful sex 

Diagnosis 

Ultrasonography of Abdomen Pelvis  Biopsy of sample tissue to confirm cancer  Hysteroscopy 

Treatment of endometrial cancer 

Total hysterectomy- removal of uterus, cervix, fallopian tubes, ovaries  Chemotherapy  Radiation  Hormonal treatment 

Treatment plans may differ from patient to patient and depends on the stage of cancer and here the patient wants to maintain fertility. 

FDA approves Immunotherapy for endometrial cancer with specific biomarker

On April 22, 2021, FDA approved the Jemprili, which works by targeting the cellular pathway. Jempreli helps the body’s immune system to help fight against the cancer cells by blocking the pathway. The safety and efficacy of Jempreli for endometrial cancer has been evaluated by FDA to expand its progress and treatment in precision medicines. 

A clinical trial was conducted for Jemprili on patients suffering from endometrial cancer. 71 patients with recurrent or advanced endometrial cancer received Jempreli showed complete or partial response with shrinkage of tumour which is effective in case of endometrial cancer patients. This immunotherapy is specifically targeted for endometrial cancer and leverages scientific knowledge surrounding the mechanism of immunotherapy response in this unmet medical need population. 

Tags : #FDA #endometrialcancer #myhealth #medicircle #Jemperli

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026